| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 42.14B | 41.38B | 36.99B | 29.94B | 102.53B | 86.08B |
| Gross Profit | 23.43B | 22.92B | 19.76B | 15.59B | 36.67B | 29.06B |
| EBITDA | 7.77B | 7.06B | 5.33B | 4.10B | 12.11B | 8.07B |
| Net Income | 3.18B | 53.78B | 1.29B | 4.25B | 5.26B | 1.48B |
Balance Sheet | ||||||
| Total Assets | 0.00 | 66.06B | 179.91B | 148.81B | 125.46B | 116.43B |
| Cash, Cash Equivalents and Short-Term Investments | 13.81B | 13.81B | 1.11B | 3.96B | 3.69B | 3.06B |
| Total Debt | 0.00 | 20.18B | 13.84B | 57.00B | 49.07B | 48.04B |
| Total Liabilities | -36.51B | 29.55B | 129.61B | 100.21B | 80.64B | 78.09B |
| Stockholders Equity | 36.51B | 34.28B | 45.60B | 44.48B | 39.53B | 33.72B |
Cash Flow | ||||||
| Free Cash Flow | 0.00 | 790.10M | -6.39B | 9.86B | 7.65B | 11.45B |
| Operating Cash Flow | 0.00 | 4.25B | 1.58B | 18.34B | 13.13B | 15.69B |
| Investing Cash Flow | 0.00 | 60.15B | -8.85B | -9.72B | -5.70B | -3.30B |
| Financing Cash Flow | 0.00 | -63.58B | 10.53B | -8.17B | -6.85B | -11.16B |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
72 Outperform | ₹332.37B | 34.13 | ― | 1.06% | 10.74% | 11.91% | |
71 Outperform | ₹382.23B | 45.01 | ― | 0.24% | 14.72% | 8.37% | |
65 Neutral | ₹265.05B | 79.88 | ― | ― | 25.74% | 1.41% | |
65 Neutral | ₹309.74B | 55.11 | ― | 0.04% | 15.78% | 15.01% | |
63 Neutral | ₹276.75B | 35.01 | ― | 1.08% | -1.51% | 14.27% | |
62 Neutral | ₹321.44B | 95.05 | ― | 0.81% | -36.14% | -93.99% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
Aster DM Healthcare Ltd. has announced its participation in upcoming investor conferences, as part of its ongoing engagement with analysts and institutional investors. These meetings, scheduled for late November 2025, will be conducted virtually, allowing the company to discuss its strategic initiatives and market opportunities without disclosing any unpublished price-sensitive information.
Aster DM Healthcare Ltd. announced its participation in upcoming investor conferences, including the J P Morgan India Emerging Opportunities Fund event. The company will engage with investors through virtual meetings, ensuring no unpublished price-sensitive information is disclosed. This participation highlights Aster DM Healthcare’s proactive approach to engaging with stakeholders and maintaining transparency in its operations.
Aster DM Healthcare Ltd. announced the cessation of Mr. Emmanuel David Gootam as a Non-Executive Independent Director, effective from the end of the day on November 9, 2025. His departure marks the completion of his first term, and he will no longer serve on the company’s Audit, Nomination and Remuneration, and Medical Excellence Committees. This change is part of the company’s compliance with the SEBI Listing Regulations, which may impact the company’s governance structure and committee dynamics.
Aster DM Healthcare Limited announced its participation in a non-deal roadshow organized by BNP Paribas in Singapore on September 25th and 26th, 2025. This engagement, involving one-on-one and group meetings, aims to enhance the company’s visibility and strengthen investor relations without sharing any unpublished price-sensitive information.